Akebia Therapeutics/$AKBA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Ticker
$AKBA
Sector
Primary listing
Employees
194
Headquarters
Website
AKBA Metrics
BasicAdvanced
$282m
-
-$0.08
0.35
-
Price and volume
Market cap
$282m
Beta
0.35
52-week high
$4.08
52-week low
$0.88
Average daily volume
4.5m
Financial strength
Current ratio
1.4
Quick ratio
1.295
Long term debt to equity
577.374
Total debt to equity
721.549
Interest coverage (TTM)
0.51%
Profitability
EBITDA (TTM)
12.13
Gross margin (TTM)
81.94%
Net profit margin (TTM)
-8.83%
Operating margin (TTM)
4.67%
Effective tax rate (TTM)
-9.33%
Revenue per employee (TTM)
$1,200,000
Management effectiveness
Return on assets (TTM)
2.02%
Return on equity (TTM)
-78.96%
Valuation
Price to revenue (TTM)
1.197
Price to book
10.28
Price to tangible book (TTM)
-8.88
Price to free cash flow (TTM)
5.328
Free cash flow yield (TTM)
18.77%
Free cash flow per share (TTM)
0.197
Growth
Revenue change (TTM)
25.69%
Earnings per share change (TTM)
-62.50%
3-year revenue growth (CAGR)
-4.98%
3-year earnings per share growth (CAGR)
-37.59%
10-year earnings per share growth (CAGR)
-29.24%
What the Analysts think about AKBA
Analyst ratings (Buy, Hold, Sell) for Akebia Therapeutics stock.
AKBA Financial Performance
Revenues and expenses
AKBA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs